Todd McKenzie

🚨 FRAUDULENT ACTORS DO NOT OPERATE IN ISOLATION — THE NETWORK OF PUBLIC PRESSURE AND REPUTATIONAL DESTRUCTION MUST BE EXPOSED EXPOSING ANGELA RASMUSSEN’S REPEATED EFFORTS TO DEFAME PROFESSOR DAVID M. SABATINI AND INTERFERE WITH HIS PROSPECTIVE PROFESSIONAL RELATIONSHIPS The ScienceGuardians™ Legal and Investigative Team is exposing a deeply troubling record of inflammatory, defamatory public attacks and efforts to undermine the prospective professional relationships of Professor @DMSabatini by Dr. Angela Rasmussen (@angie_rasmussen), Principal Research Scientist at the Vaccine and Infectious Disease Organization (VIDO, @VIDOInterVac), University of Saskatchewan (@usask), and Co-Editor-in-Chief of Vaccine, published by Elsevier, in 2021 and 2022. THE DOCUMENTARY EVIDENCE SPEAKS FOR ITSELF. In August 2021, Rasmussen publicly described Sabatini as one of the: 🔴 “worthless bastards” She went further, referring to: 🔴 “the destruction he and all his fellow entitled ethically bankrupt abusive bastards leave in their wake.” In April 2022, as Sabatini faced intense public pressure over a prospective appointment at NYU Langone Health, Rasmussen continued her attacks, describing him as: 🔴 “an unrepentant sex abuser” 🔴 “one powerful and well-connected sexual harasser” She further asserted that he had been: 🔴 “pushed out of 3 institutions for abhorrent and repeated sexual misconduct.” BUT THE MOST DISTURBING EVIDENCE CONCERNS HER DIRECT INTERVENTION IN SABATINI’S PROFESSIONAL FUTURE. Rather than limiting herself to expressing opinions, Rasmussen directly addressed his prospective employer, @nyulangone, declaring: 🔴 “I’m content to inform all 365K of my Twitter followers what hiring David Sabatini says about your institutional values & integrity.” She subsequently encouraged another user: 🔴 “I encourage you to tag @nyulangone when discussing why they are hiring David Sabatini despite his long record of appalling conduct.” 365,000 FOLLOWERS. A PROSPECTIVE EMPLOYER. DIRECT PUBLIC PRESSURE. AN EXPLICIT CALL FOR OTHERS TO TAG THAT EMPLOYER. These communications document Rasmussen’s deliberate efforts to mobilize public pressure against Sabatini’s prospective employer, NYU Langone Health, and undermine his professional opportunities. THEN CAME THE JURY VERDICT. On October 16, 2026, a Massachusetts jury found Kristin Knouse liable for defamation and tortious interference with Sabatini’s professional relationships, awarding him $6 million in damages — approximately $9.6 million including prejudgment interest. That verdict was against Kristin Knouse, not Rasmussen. But it makes independent scrutiny of Rasmussen’s conduct all the more important. PUBLICLY AMPLIFYING SERIOUS ACCUSATIONS WITHOUT ADEQUATE DUE DILIGENCE IS NOT ACCOUNTABILITY. TARGETING A SCIENTIST’S PROSPECTIVE EMPLOYER AND ENCOURAGING OTHERS TO APPLY PRESSURE IS NOT SCIENTIFIC DEBATE. The central issue is not simply what Rasmussen said. It is what she sought to accomplish by directing those statements toward an institution considering Sabatini’s employment. ⚠️ The University of Saskatchewan and VIDO must confront the documented conduct of their affiliated researcher and determine whether it complied with their professional and institutional standards. A JURY HAS ALREADY ESTABLISHED LIABILITY FOR DEFAMATION AND TORTIOUS INTERFERENCE IN THIS ORDEAL. THE CONDUCT OF OTHERS WHO PUBLICLY CONTRIBUTED TO THE PRESSURE AGAINST SABATINI DESERVES ITS OWN INDEPENDENT EXAMINATION AND, WHERE WRONGDOING IS ESTABLISHED, FULL ACCOUNTABILITY. 📑 Examine the accompanying documentary evidence. Scan the QR codes beside the screenshots to access the original sources. 🔱 ScienceGuardians™ Legal and Investigative Team ⚠️ MORE REVELATIONS CONCERNING ANGELA RASMUSSEN’S CONDUCT ARE COMING. 🔱 FOLLOW @SciGuardians. STAY TUNED.

Your mitochondria can trigger the same inflammatory alarms your immune system uses to fight bacteria. That's because mitochondria are bacteria, or at least they were 1.5 billion years ago. A Nature Reviews Immunology paper maps the molecular mechanisms of how mitochondria control inflammation, the safeguards that normally prevent false alarms, and what happens when those systems fail. The core problem: mitochondria are ancient bacteria that your cells absorbed roughly 1.5 billion years ago. They still carry bacterial signatures. Your immune system evolved to recognize bacterial molecules as threats. When mitochondria get damaged and leak their contents, your immune system can't distinguish between a broken mitochondrion and an actual infection. Mitochondria contain multiple damage-associated molecular patterns, or DAMPs. These are molecules that trigger immune responses when detected outside their normal location: • Mitochondrial DNA (mtDNA): Unmethylated, circular DNA that resembles bacterial genomes • Cardiolipin: A phospholipid normally confined to the inner mitochondrial membrane • N-formyl peptides: Proteins with bacterial-style chemical signatures • ATP and other metabolites: Energy molecules that signal danger when released These molecules activate pattern recognition receptors, the sensors your immune system uses to detect threats. The most studied pathway involves mitochondrial DNA activating a detection system called cGAS-STING. Here's how it works: When mitochondria become damaged, their outer membrane develops holes. Think of it like a breach in a container. The mitochondrial DNA, which normally stays sealed inside, leaks out into the cytosol, the liquid interior of your cell. An enzyme called cGAS patrols the cytosol looking for DNA that shouldn't be there. When it finds mitochondrial DNA floating around, it produces a signaling molecule called cGAMP. This molecule activates another protein called STING, which sits on the endoplasmic reticulum, a membrane network inside cells. STING activation triggers the production of interferons, immune signaling proteins your body normally makes to fight viral infections. Your cell responds to leaked mitochondrial DNA the same way it responds to a virus. A second pathway involves cardiolipin, a fat molecule that normally stays on the inner membrane of mitochondria. When cardiolipin appears on the outer surface or leaks into the cytosol, it activates the NLRP3 inflammasome. This is a multi-protein assembly that acts like an alarm system. Once activated, it produces inflammatory molecules called cytokines, specifically IL-1β, which trigger inflammation throughout surrounding tissue. Your cells have multiple safeguards to prevent mitochondria from triggering these inflammatory pathways: Apoptosis suppresses inflammation. Apoptosis is programmed cell death, a controlled self-destruction process. When a cell commits to dying, it activates enzymes called caspases. These enzymes act like molecular scissors, rapidly cutting up mitochondrial DNA and other inflammatory molecules before they can activate immune sensors. Two key studies demonstrated that strong caspase activation prevents the cGAS-STING pathway from turning on during cell death. Mitophagy removes damaged mitochondria. Mitophagy is selective autophagy, meaning cellular recycling that targets only mitochondria. When mitochondria lose their electrical charge, called membrane potential, or accumulate too much damage, they get tagged with molecular markers. These tags signal cellular machinery to engulf the damaged mitochondrion inside a double-membrane structure called an autophagosome. The autophagosome fuses with a lysosome, which contains digestive enzymes that break down the damaged mitochondrion completely. This happens before its contents can leak out and trigger inflammation. Chromatin packaging inhibits cGAS. Your nuclear DNA is wrapped around proteins called histones and packaged into a structure called chromatin. This packaging prevents cGAS from detecting it. Mitochondrial DNA lacks this protective packaging, which makes it a much stronger activator of cGAS when it reaches the cytosol. This difference explains why leaked mitochondrial DNA triggers inflammation while nuclear DNA, even when exposed during normal cell division, generally does not. The pathological consequences emerge when these safeguards fail or get overwhelmed. Insufficient mitophagy allows damaged mitochondria to accumulate. Their contents gradually leak into the cytosol, triggering chronic low-grade inflammation. This process contributes to age-related inflammatory diseases, neurodegenerative disorders, and metabolic dysfunction. Defective apoptosis prevents proper DAMP degradation. Cells that can't complete programmed death release intact mitochondrial components that activate stronger inflammatory responses. This mechanism appears in some autoimmune conditions where defective clearance of dying cells drives chronic inflammation. Excessive mitochondrial stress overwhelms quality control. When mitochondrial damage happens faster than mitophagy can remove it, cells release mitochondrial DAMPs even with functioning safeguards. This occurs during ischemia-reperfusion injury, severe metabolic stress, and certain infections that specifically target mitochondria. The inflammation can become bidirectional. Inflammatory signals like TNF-α and interferons feed back to impair mitochondrial function, creating cycles where inflammation damages mitochondria and damaged mitochondria amplify inflammation. Several human diseases show clear links to dysregulated mitochondria-driven inflammation: Parkinson's disease involves mitochondrial dysfunction in dopaminergic neurons. Defective mitophagy allows damaged mitochondria to trigger inflammatory responses that accelerate neurodegeneration. Systemic lupus erythematosus shows elevated mtDNA in circulation and enhanced cGAS-STING activation. Defective clearance of dying cells releases mitochondrial contents that drive autoantibody production. COVID-19 severity correlates with cGAS-STING pathway activation. Viral infection triggers mitochondrial DNA release, and excessive type I interferon responses contribute to immunopathology. Cancer cells sometimes exploit insufficient mitochondria-driven inflammation. Tumors with defective inflammatory signaling evade immune surveillance, while therapeutic interventions that trigger controlled mitochondrial DAMP release can enhance anti-tumor immunity. The therapeutic implications point in two directions. For inflammatory diseases, blocking mitochondrial DAMP signaling could reduce pathological inflammation. cGAS-STING inhibitors are in development for autoimmune conditions. Enhancing mitophagy might prevent DAMP accumulation before inflammation starts. For cancer and infections, activating mitochondrial DAMP release could boost immunity. Some chemotherapy drugs work partly by triggering immunogenic cell death that releases mitochondrial DAMPs. Radiation therapy activates similar pathways. The central insight is that mitochondrial quality control and inflammation are mechanistically linked. The same cellular machinery that maintains energy metabolism also determines inflammatory state. When mitochondria function properly and damaged ones get cleared efficiently, inflammation remains appropriately regulated. When quality control fails, mitochondrial DAMPs drive pathological inflammatory responses. Your immune system treats broken mitochondria like invading bacteria because, evolutionarily, that's exactly what they once were. The molecular signatures persist. What determines health versus disease is how effectively your cells maintain mitochondrial integrity and clear damaged mitochondria before they trigger inappropriate immune activation.

GENTHERAPIE UND TUMORRISIKO: FDA BESTÄTIGT INSERTIONSONKOGENESE BEI ZOLGENSMA Die US-Arzneimittelbehörde FDA untersucht ein schwerwiegendes Sicherheitssignal bei der Gentherapie Zolgensma (Onasemnogen-Abeparvovec) des Pharmakonzerns Novartis. Seit der Zulassung 2019 wurden neun Tumorfälle bei behandelten Kindern gemeldet. In zwei Fällen konnte molekulargenetisch nachgewiesen werden, dass DNA des verwendeten AAV-Vektors in das menschliche Genom integriert wurde – im Bereich des Onkogens GLI1. Der entscheidende Befund: Die FDA spricht ausdrücklich von produktbedingter Insertionsonkogenese. Durch die Integration von Vektor-DNA kann die Genregulation gestört und die Tumorentstehung begünstigt werden. Das bislang als theoretisch beschriebene Risiko hat damit eine konkrete molekulare Grundlage erhalten. Mehr als 6.000 Kinder wurden weltweit mit Zolgensma behandelt. Die FDA bewertet das Nutzen-Risiko-Verhältnis bei spinaler Muskelatrophie weiterhin positiv. Journalistisch und regulatorisch stellen sich nun entscheidende Fragen: Wann lagen dem Hersteller die ersten Hinweise vor? Wann wurden FDA, EMA und nationale Behörden informiert? Welche Konsequenzen ergeben sich für die Langzeitüberwachung AAV-basierter Gentherapien? Bei einer Therapie, deren Einführungspreis rund 2,1 Millionen US-Dollar betrug, müssen Wirksamkeit, Langzeitsicherheit und Transparenz gleichermaßen überprüfbar sein. Quelle: FDA Safety Communication, 06.11.2026 #Zolgensma #Novartis #Gentherapie #FDA #Pharmakovigilanz

Extrachromosomal DNA hubs act as redox reactors that shield amplified oncogenes Molecular Cell · current issue · Mechanism cell.com/molecular-cell/full…